Quick Facts

Chemical Name
Larazotide Acetate
Also Known As
AT-1001, INN-202
Category
Gut Health
Administration
Oral capsule or solution

What is Larazotide?

Larazotide acetate is a synthetic octapeptide derived from Vibrio cholerae zonula occludens toxin. Unlike the toxin, larazotide tightens rather than loosens intestinal junctions. It was developed by Alba Therapeutics for celiac disease treatment and has reached Phase 3 clinical trials. By preventing excessive intestinal permeability, larazotide may reduce the immune response triggered by gluten exposure.

How Does Larazotide Work?

Larazotide works by regulating tight junctions between intestinal epithelial cells. It antagonizes the zonulin receptor, preventing the signaling that leads to tight junction opening. This reduces 'leaky gut' by maintaining the intestinal barrier. In celiac disease, this prevents gluten peptides from crossing into the lamina propria where they trigger immune responses.

Research-Backed Benefits

Tight Junction Regulation

Strong Evidence

Directly addresses intestinal permeability at the cellular level.

Celiac Disease Support

Strong Evidence

Reduces symptoms of gluten exposure in celiac patients.

Leaky Gut Treatment

Moderate Evidence

May benefit other conditions involving intestinal permeability.

Oral Administration

Strong Evidence

Taken orally, works locally in the gut.

Dosage Guidelines

Disclaimer: This content is for educational purposes only. Peptides are research compounds not approved by the FDA for human use. Always consult with a qualified healthcare provider.

Typical Range
0.5-2 mg per dose
Frequency
3 times daily with meals
Duration
Ongoing during gluten exposure risk

Taken before meals to prevent gluten-induced permeability. Not a license to eat gluten for celiacs.

Side Effects & Safety

  • Generally well tolerated
  • Headache
  • Upper respiratory symptoms
  • Nausea (uncommon)

Frequently Asked Questions

No, Larazotide reduces symptoms from accidental gluten exposure but is not a cure. A gluten-free diet remains essential for celiac patients.
Larazotide has completed Phase 3 trials for celiac disease but is not yet FDA approved. It remains the most advanced therapeutic specifically targeting intestinal permeability.
Research is primarily in celiac disease, but the mechanism suggests potential for other conditions involving intestinal permeability. More research is needed.

References

  1. Leffler DA, et al. "Larazotide celiac trials." Gastroenterology, 2015. PMID: 26195443

Get the Complete Larazotide Research Protocol

Join 50,000+ researchers with instant access to our comprehensive peptide resource.

Continue Your Research

Explore by Condition